Immuneering (IMRX) Revenue (2020 - 2022)

Immuneering (IMRX) has reported Revenue for 3 consecutive years, with $455.0 the latest figure, recorded in Q4 2022.

• In Q4 2022, Revenue fell 99.76% year-over-year to $455.0; the TTM figure through Sep 2023 stood at $455.0 (down 99.91% YoY), while the FY2022 annual figure was $316952.0, down 84.76% from the prior year.
• Revenue came in at $455.0 for Q4 2022 at Immuneering, down from $38380.0 in the prior quarter.
• The five-year high for Revenue was $748200.0 in Q1 2021, with the low at $455.0 in Q4 2022.
• Average Revenue over 3 years is $384127.1, with a median of $480835.0 recorded in 2020.
• Across the five-year window, Revenue jumped 37.27% in 2021 and sank 99.76% in 2022, its largest moves.
• Year by year, Revenue stood at $665080.0 in 2020, then sank by 71.49% to $189591.0 in 2021, then tumbled by 99.76% to $455.0 in 2022.
• According to Business Quant data, Revenue over the past three periods registered $455.0, $38380.0, and $94419.0 for Q4 2022, Q3 2022, and Q2 2022 respectively.